- Home
- LDWY vs BIAF Comparison
LDWY vs BIAF Comparison
Compare LDWY & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LDWY | BIAF |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 6.8M |
| IPO Year | 1991 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LDWY | BIAF |
|---|---|---|
| Price | $3.40 | $1.27 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 51.7K | ★ 78.0K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $69,769,000.00 | $6,776,739.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.04 |
| P/E Ratio | $4.80 | ★ N/A |
| Revenue Growth | ★ 121.91 | N/A |
| 52 Week Low | $3.11 | $1.18 |
| 52 Week High | $6.19 | $46.53 |
Technical Indicators
Market Signals| Indicator | LDWY | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 43.33 | 36.10 |
| Support Level | $3.20 | $1.18 |
| Resistance Level | $3.45 | $1.74 |
| Average True Range (ATR) | 0.30 | 0.13 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 19.64 | 17.90 |
Price Performance
Historical ComparisonAbout LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in industries: Specialty Ag, consisting of the Bloomia business.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.